Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences
Rhea-AI Summary
Corbus Pharmaceuticals (Nasdaq: CRBP), a clinical-stage company in oncology and obesity, announced that CEO Yuval Cohen will present a corporate overview and hold investor meetings at the RBC Capital Markets Global Healthcare Conference on May 19, 2026, and the Jefferies Global Healthcare Conference on June 4, 2026, both in New York.
Presentations will be webcast. Corbus’ pipeline includes CRB-701, a next-generation antibody drug conjugate targeting Nectin-4-expressing tumors, and CRB-913, an oral, highly peripherally restricted CB1 inverse agonist for obesity.
Positive
- None.
Negative
- None.
News Market Reaction – CRBP
In the May 13 session, CRBP gained 6.30%, reflecting a notable positive market reaction. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NORWOOD, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP), a clinical-stage company focused on developing promising new therapies in oncology and obesity, today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will present a corporate overview and attend investor meetings at both the RBC Capital Markets Global Healthcare Conference being held in New York on May 19 – 20, 2026, and the Jefferies Global Healthcare Conference being held in New York on June 2 - 4, 2026.
| RBC Capital Markets Global Healthcare Conference | |
| Format: | Presentation and one-on-one investor meetings |
| Date: | Tuesday, May 19, 2026 |
| Time: | 2:05pm EDT |
| Webcast: | Click here |
| Jefferies Global Healthcare Conference | |
| Format: | Presentation and one-on-one investor meetings |
| Date: | Thursday, June 4, 2026 |
| Time: | 4:55pm EDT |
| Webcast: | Click here |
About Corbus
Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage company focused on developing promising new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing innovative scientific approaches to well-understood biological pathways. Corbus’ pipeline includes CRB-701, a next-generation antibody drug conjugate for the treatment of Nectin-4-expressing tumors, and CRB-913, an orally delivered highly peripherally restricted CB1 inverse agonist for the treatment of obesity. Corbus is headquartered in Norwood, Massachusetts. For more information on Corbus, visit corbuspharma.com. Connect with us on X, LinkedIn and Facebook.
Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act of 1995, as amended, including those relating to the Company’s trial results, product development, clinical and regulatory timelines, including timing for completion of trials and presentation of data, anticipated regulatory interactions and outcomes, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities, sufficiency of cash runway and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions.
These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors on our operations, clinical development plans and timelines, which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company’s filings with the Securities and Exchange Commission including those described in our Annual Report on Form 10-K for the year ended December 31, 2025. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.
All product names, logos, brands and company names are trademarks or registered trademarks of their respective owners. Their use does not imply affiliation or endorsement by these companies.
INVESTOR CONTACTS:
Sean Moran
Chief Financial Officer
Corbus Pharmaceuticals
smoran@corbuspharma.com
Dan Ferry
Managing Director
LifeSci Advisors, LLC
daniel@lifesciadvisors.com
MEDIA CONTACT:
Liz Melone
Founder & Principal
Melone Communications, LLC
liz@melonecomm.com
